Horizon Pharma PLC (HZNP) Position Trimmed by Foundry Partners LLC

Foundry Partners LLC cut its holdings in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 6.1% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 120,095 shares of the biopharmaceutical company’s stock after selling 7,746 shares during the quarter. Foundry Partners LLC’s holdings in Horizon Pharma were worth $3,174,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Private Capital Group LLC lifted its position in Horizon Pharma by 141.5% during the fourth quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,150 shares during the period. SG Americas Securities LLC lifted its position in Horizon Pharma by 79.5% during the fourth quarter. SG Americas Securities LLC now owns 9,438 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 4,179 shares during the period. Meeder Asset Management Inc. lifted its position in Horizon Pharma by 631.9% during the fourth quarter. Meeder Asset Management Inc. now owns 9,947 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 8,588 shares during the period. D.A. Davidson & CO. lifted its position in Horizon Pharma by 5.1% during the fourth quarter. D.A. Davidson & CO. now owns 10,592 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 512 shares during the period. Finally, Keybank National Association OH purchased a new position in Horizon Pharma during the fourth quarter worth about $209,000. Hedge funds and other institutional investors own 82.05% of the company’s stock.

In related news, EVP Geoffrey M. Curtis sold 8,835 shares of the firm’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $23.15, for a total transaction of $204,530.25. Following the sale, the executive vice president now directly owns 32,202 shares in the company, valued at approximately $745,476.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Geoffrey M. Curtis sold 10,080 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $21.21, for a total value of $213,796.80. Following the sale, the executive vice president now owns 35,367 shares of the company’s stock, valued at approximately $750,134.07. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

Shares of NASDAQ:HZNP opened at $25.30 on Friday. The stock has a market cap of $4.67 billion, a P/E ratio of 13.83, a P/E/G ratio of 1.44 and a beta of 1.14. The company has a current ratio of 2.03, a quick ratio of 1.97 and a debt-to-equity ratio of 1.80. Horizon Pharma PLC has a one year low of $12.55 and a one year high of $29.44.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.54 by $0.13. The business had revenue of $355.50 million for the quarter, compared to the consensus estimate of $334.22 million. Horizon Pharma had a positive return on equity of 34.09% and a negative net margin of 6.34%. The company’s revenue was up 29.6% on a year-over-year basis. During the same period last year, the business posted $0.29 EPS. On average, equities analysts forecast that Horizon Pharma PLC will post 1.7 earnings per share for the current year.

A number of equities analysts have recently commented on HZNP shares. Morgan Stanley upgraded Horizon Pharma from an “equal weight” rating to an “overweight” rating and set a $32.00 price objective on the stock in a report on Friday, March 8th. Cowen set a $33.00 price objective on Horizon Pharma and gave the stock a “buy” rating in a report on Thursday, February 28th. BidaskClub downgraded Horizon Pharma from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. Mizuho restated a “hold” rating and issued a $21.00 price objective on shares of Horizon Pharma in a report on Thursday, February 7th. Finally, JMP Securities raised their price objective on Horizon Pharma from $26.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $30.73.

WARNING: This piece of content was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/horizon-pharma-plc-hznp-position-trimmed-by-foundry-partners-llc.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Recommended Story: Do You Need a Fiduciary?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.